From Pulse 2.0 · Amit Chowdhry · · 40s
Xylyx Bio Gets FDA Orphan Designation And NIH Grant
Xylyx Bio receives FDA orphan drug status and $2.99m NIH grant for Inspirex Lung.
In brief
Xylyx Bio receives FDA orphan drug status and $2.99m NIH grant for Inspirex Lung. Xylyx Bio's Inspirex Lung, a bioengineered lung graft for patients with lung failure, gets FDA orphan drug designation and $2.99 million NIH grant to advance development. Originally reported by Pulse 2.0.
FDA Orphan Designation
Xylyx Bio receives FDA orphan drug designation for Inspirex Lung.
NIH Grant Funding
NIH provides $2.99 million for Inspirex Lung safety and feasibility studies.
Inspirex Lung Purpose
Inspirex Lung repairs injured donor lungs to increase transplant availability.
The essence
Xylyx Bio's Inspirex Lung, a bioengineered lung graft for patients with lung failure, gets FDA orphan drug designation and $2.99 million NIH grant to advance development.
